Cue Biopharma, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-26.6M | $-40.7M | $-50.7M | $-53.0M | $-44.2M | $-44.8M | $-36.7M | $-39.0M |
| Depreciation & Amortization | $958.0K | $397.0K | $556.0K | $922.0K | $1.3M | $1.1M | $810.8K | $760.0K |
| Depreciation | $336.0K | $385.0K | $545.0K | $831.0K | $909.1K | $780.5K | $799.1K | $760.0K |
| Amortization | — | — | — | — | — | $11.7K | $11.7K | — |
| Stock-Based Compensation | $4.7M | $6.8M | $8.2M | $9.5M | $11.5M | $10.5M | $6.5M | $7.2M |
| Net Cash from Operating Activities | $-21.7M | $-36.3M | $-40.0M | $-41.8M | $-38.8M | $-32.5M | $-30.8M | $-26.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $177.0K | $66.0K | $0 | $171.0K | $913.0K | $595.3K | $46.4K | $1.9M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $75.0K | $32.0K | $25.0M | $-24.6M | $9.1M | $4.5M | $3.4M | $-20.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | $0 | $200.0K | $750.1K | $271.1K | $91.0K | — |
| Net Cash from Financing Activities | $26.3M | $10.2M | $11.9M | $53.7M | $19.2M | $58.6M | $50.8M | $4.2M |
| Net Change in Cash | $4.7M | $-26.1M | $-3.1M | $-12.8M | $-10.5M | $30.6M | $23.4M | $-42.6M |
| Free Cash Flow | $-21.9M | $-36.4M | $-40.0M | $-42.0M | $-39.8M | $-33.1M | $-30.8M | $-28.3M |